Kymera Therapeutics' Founder & CEO Nello Mainolfi recaps Monday's STAT6 data and discusses the next steps in development
- blonca9
- Dec 10, 2025
- 1 min read
He talks about Kymera's dosing methodology, and recaps the data from a degradation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.














.png)

